Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) have been assigned a consensus rating of “Buy” from the twelve analysts that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $14.75.
Several brokerages recently issued reports on MRTX. BidaskClub raised shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. ValuEngine raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. HC Wainwright lifted their price target on shares of Mirati Therapeutics from $17.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Oppenheimer set a $18.00 price target on shares of Mirati Therapeutics and gave the company a “buy” rating in a report on Monday, January 8th. Finally, Cann reaffirmed a “buy” rating and set a $18.00 price target on shares of Mirati Therapeutics in a report on Monday, January 8th.
In related news, SVP Jamie Christensen sold 10,814 shares of Mirati Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $27.00, for a total transaction of $291,978.00. Following the sale, the senior vice president now directly owns 13,691 shares of the company’s stock, valued at approximately $369,657. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 61,039 shares of company stock worth $1,646,881 over the last ninety days. 5.10% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in Mirati Therapeutics by 57.5% during the 4th quarter. BlackRock Inc. now owns 510,362 shares of the biotechnology company’s stock worth $9,314,000 after acquiring an additional 186,419 shares during the last quarter. Jennison Associates LLC bought a new stake in Mirati Therapeutics during the 4th quarter worth approximately $8,899,000. Dimensional Fund Advisors LP grew its holdings in Mirati Therapeutics by 68.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock worth $3,939,000 after acquiring an additional 137,104 shares during the last quarter. Geode Capital Management LLC grew its holdings in Mirati Therapeutics by 8.7% during the 4th quarter. Geode Capital Management LLC now owns 184,406 shares of the biotechnology company’s stock worth $3,365,000 after acquiring an additional 14,721 shares during the last quarter. Finally, Rock Springs Capital Management LP bought a new stake in Mirati Therapeutics during the 4th quarter worth approximately $3,285,000. 67.85% of the stock is currently owned by hedge funds and other institutional investors.
Mirati Therapeutics (MRTX) opened at $29.60 on Tuesday. The company has a market cap of $799.01, a P/E ratio of -9.52 and a beta of 2.17. Mirati Therapeutics has a 12-month low of $2.70 and a 12-month high of $30.50.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/20/mirati-therapeutics-inc-mrtx-given-consensus-recommendation-of-buy-by-brokerages.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.